617 related articles for article (PubMed ID: 11769299)
1. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
3. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
[TBL] [Abstract][Full Text] [Related]
4. Lansoprazole overutilization: methods for step-down therapy.
Pohland CJ; Scavnicky SA; Lasky SS; Good CB
Am J Manag Care; 2003 May; 9(5):353-8. PubMed ID: 12744297
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
6. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy.
Condra LJ; Morreale AP; Stolley SN; Marcus D
Am J Manag Care; 1999 May; 5(5):631-8. PubMed ID: 10537869
[TBL] [Abstract][Full Text] [Related]
7. Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Bailie GR; Mason NA; Elder SJ; Andreucci VE; Greenwood RN; Akiba T; Saito A; Bragg-Gresham JL; Gillespie BW; Young EW
Hemodial Int; 2006 Apr; 10(2):180-8. PubMed ID: 16623672
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors. Compliance with a mandated step-up program.
Mamdani MM; Tu K; Jaakkimainen L; Bica A; Hux J
Can Fam Physician; 2001 Mar; 47():531-5. PubMed ID: 11281086
[TBL] [Abstract][Full Text] [Related]
9. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor utilization patterns in infants.
Barron JJ; Tan H; Spalding J; Bakst AW; Singer J
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):421-7. PubMed ID: 18030207
[TBL] [Abstract][Full Text] [Related]
11. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Hall J; Dodd S; Durkin M; Sloan S
Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
[TBL] [Abstract][Full Text] [Related]
12. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.
El-Serag HB; Fitzgerald S; Richardson P
Am J Gastroenterol; 2009 Sep; 104(9):2161-7. PubMed ID: 19568229
[TBL] [Abstract][Full Text] [Related]
13. Rational prescribing: practice audit and drug switch in dyspepsia management.
Dott AG; Johnson L
Int J Clin Pract; 1999 Dec; 53(8):599-603. PubMed ID: 10692753
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
[TBL] [Abstract][Full Text] [Related]
15. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J
Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of use of proton pump inhibitors in Greece.
Ntaios G; Chatzinikolaou A; Kaiafa G; Savopoulos C; Hatzitolios A; Karamitsos D
Eur J Intern Med; 2009 Mar; 20(2):171-3. PubMed ID: 19327607
[TBL] [Abstract][Full Text] [Related]
17. A simple institutional educational intervention to decrease use of selected expensive medications.
Roth EJ; Plastaras CT; Mullin MS; Fillmore J; Moses ML
Arch Phys Med Rehabil; 2001 May; 82(5):633-6. PubMed ID: 11346840
[TBL] [Abstract][Full Text] [Related]
18. Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders.
Bursey F; Crowley M; Janes C; Turner CJ
CMAJ; 2000 Mar; 162(6):817-23. PubMed ID: 10750472
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors: perspectives of patients and their GPs.
Grime J; Pollock K; Blenkinsopp A
Br J Gen Pract; 2001 Sep; 51(470):703-11. PubMed ID: 11593830
[TBL] [Abstract][Full Text] [Related]
20. Reducing outpatient costs of nonsteroidal antiinflammatory drugs at a Department of Veterans Affairs teaching hospital.
Drexler PG; Lambdin CS
J Pharm Technol; 1993; 9(1):10-3. PubMed ID: 10123760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
